Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives Ronaldo A. RibeiroCarlos W. S. WanderleyRoberto C. P. Lima-JĂşnior Review Article 02 September 2016 Pages: 881 - 893
Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas Michael J. NathensonEdward Sausville Review Article 20 May 2016 Pages: 895 - 919
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors John SarantopoulosSanjay GoelSunil Sharma Original Article 28 September 2016 Pages: 921 - 927
Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment Kevin R. KellyNashat GabrailA. Craig Lockhart Original Article 16 September 2016 Pages: 929 - 939
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience Naohiro OdaKatsuyuki HottaKatsuyuki Kiura Original Article 02 September 2016 Pages: 941 - 947
A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer Boram HanJoo Young JungDae Young Zang Original Article 15 September 2016 Pages: 949 - 958
Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors Martin J. EdelmanRena LapidusJogarao Gobbru Original Article 12 September 2016 Pages: 959 - 967
Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors Martin J. EdelmanRena LapidusJogarao Gobburu Erratum 27 September 2016 Pages: 969 - 969
JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo Cong WangRan WangHongmin Liu Original Article 12 September 2016 Pages: 971 - 982
Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia Stine Nygaard NielsenKathrine GrellKjeld Schmiegelow Original Article 06 September 2016 Pages: 983 - 994
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors Yosuke TamuraHiroshi NokiharaTomohide Tamura Original Article 15 September 2016 Pages: 995 - 1002
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study Wijith MunasingheSven StodtmannHao Xiong Original Article Open access 05 October 2016 Pages: 1003 - 1011
Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer Masato FukaeYoshimasa ShiraishiIchiro Ieiri Original Article 05 October 2016 Pages: 1013 - 1023
The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells Xu WangBo YangBaojing Ma Original Article 29 September 2016 Pages: 1025 - 1031
Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats Alexandre IarkovDoreen AppunnValentina Echeverria Original Article 05 October 2016 Pages: 1033 - 1039
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma Soushi IbataTsutomu SatoJunji Kato Original Article Open access 13 October 2016 Pages: 1041 - 1049
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia Savitha VaratharajanJohn C. PanettaPoonkuzhali Balasubramanian Original Article 13 October 2016 Pages: 1051 - 1058
A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors Hanna BaileyJordan P. McPhersonNeeraj Agarwal Original Article 15 October 2016 Pages: 1059 - 1071
Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma Saeed ZavarehMilad MahdiHamid Hashemi-Moghaddam Original Article 17 October 2016 Pages: 1073 - 1084
Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma Jong-Ho KimIn-Gu DoOn Behalf of the KBSMC Pancreatobiliary Cancer Team Original Article 15 October 2016 Pages: 1085 - 1092
Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients Victoria J. ForsterFrederik W. van DelftChristina Halsey Short Communication Open access 22 September 2016 Pages: 1093 - 1096
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing? Nuggehally R. Srinivas Letter to the Editor 13 May 2016 Pages: 1097 - 1098
15-0600-Dr. Fox’s response to letter to the editor Elizabeth FoxFrank M. Balis Letter to the Editor 11 October 2016 Pages: 1099 - 1100